Systemic Sclerosis-associated Interstitial Lung Disease
📧 Sign up to get email alerts when something new happens for Systemic Sclerosis-associated Interstitial Lung Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease [Phase 3]
Phase 3 clinical trial assessing efficacy and safety of pirfenidone in systemic sclerosis-associated interstitial lung disease.
-
CLINICAL_TRIALS trial_result · 2016-07-12Clinical Trial Update: Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases
This clinical trial update covers idiopathic pulmonary fibrosis, focusing on pathogenesis and staging within the SCOR framework for occupati…
-
FDA approval · 2016-02-04FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for OFEV (nintedanib) filed by Boehringer Ingelheim Pharmaceuticals, Inc., expanding its approved us…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
A completed clinical trial update evaluating the role of gastroesophageal reflux, microaspiration, and cough in scleroderma lung.
-
CLINICAL_TRIALS trial_result · 2015-04-21Clinical Trial Update: A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma [Phase 3]
Reports the completion of a Phase 3 trial evaluating tadalafil for systemic sclerosis-associated interstitial lung disease (scleroderma).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.